Skip to content
Tokyo Brief東 京 ブ リ ー フJapan's day, wrapped and delivered by morning.
Company
Companies

SanBio

サンバイオ

4592 · TSE · Pharmaceutical · 3 articles

Financials Consolidated

Ordinary profit−¥4.29bnConsolidated · FY1/26

Net profit−¥3.84bnConsolidated · FY1/26

Performance over time

Ordinary profit
−¥4.58bnFY1/22
−¥4.70bnFY1/23
−¥2.82bnFY1/24
−¥3.02bnFY1/25
−¥4.29bnFY1/26
Net profit (attributable)
−¥4.68bnFY1/22
−¥5.56bnFY1/23
−¥2.64bnFY1/24
−¥2.88bnFY1/25
−¥3.84bnFY1/26
Op. cash flow
−¥6.55bnFY1/22
−¥7.43bnFY1/23
−¥4.77bnFY1/24
−¥3.60bnFY1/25
−¥3.76bnFY1/26

People & pay

Employees, whole group33 peopleFY1/26

Employees, parent company (non-consolidated)33 peopleFY1/26

Average salary¥20.2mFY1/26

Average salary is for the parent company's own employees (non-consolidated), as Japanese annual reports disclose it.

Five-year history
Five-year history
Fiscal yearOrdinary profitNet profit (attributable)EPSTotal assetsNet assetsOp. cash flow
FY1/26−¥4.29bn−¥3.84bn−¥52.55¥15.62bn¥13.60bn−¥3.76bn
FY1/25−¥3.02bn−¥2.88bn−¥41.86¥3.45bn¥1.76bn−¥3.60bn
FY1/24−¥2.82bn−¥2.64bn−¥40.48¥5.05bn¥2.79bn−¥4.77bn
FY1/23−¥4.70bn−¥5.56bn−¥95.99¥7.05bn¥4.43bn−¥7.43bn
FY1/22−¥4.58bn−¥4.68bn−¥90.33¥5.51bn¥2.04bn−¥6.55bn

Per-share figures are as each report states them: a share split is restated only for the year before it, and dividends are as paid.

Figures from annual report S100XZTW · Japan GAAP. Each figure's years come from one report's five-year summary.

Latest coverage

TSE:4592

Tokyo Brief coverage

  1. SanBio Targets Just Six Patients for Its ¥72.7mn Brain Therapy This Year

    SanBio's newly launched cell therapy for chronic motor paralysis after traumatic brain injury, priced at ¥72.7mn a treatment, has generated no revenue and no dosed patients four months after its Japanese launch, and the company is now targeting only six cases by the fiscal year-end in January while its cash pile fell ¥2.34bn to ¥12.75bn over the same half-year.

  2. SanBio's SB623 Therapy Reaches Market at ¥72mn, But Revenue Stays at Zero

    SanBio's cell therapy for chronic traumatic brain injury, known by its development code SB623, cleared its final approval hurdle and reached the market in 2026 with a ¥72mn price tag, yet the company's latest results show no product revenue, a shrinking cash pile, and a 20.29% cut to capital to offset accumulated losses.

All articles loaded · 3 shown

Fund positioning

Current holdings disclosed by tracked funds.

4 funds · data through

Held by 4 tracked funds; largest weight 1.71%. Holdings as of 31 Aug 2026–19 Nov 2026.